Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Benzinga Insights

Rhythm Pharmaceuticals Earnings Perspective: Return On Capital Employed

Benzinga Pro data, Rhythm Pharmaceuticals (NASDAQ:RYTM) reported Q4 sales of $1.82 million. Earnings fell to a loss of $42.87 million, resulting in a 22.1% decrease from last quarter. In Q3, Rhythm Pharmaceuticals brought in $1.03 million in sales but lost $35.11 million in earnings.

Why Is ROCE Significant?

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.